media1

Group News

Aspen opens R1 billion high containment facility

May 7, 2018

Port Elizabeth – JSE Limited-listed Aspen Pharmacare (APN), South Africa’s largest pharmaceutical company, officially opened its R1 billion Port Elizabeth-based high containment facility earlier today. Stephen Saad, Aspen Group Chief Executive said, “Aspen continues its evolution into a global specialty manufacturer of niche products requiring complex technologies. The high potency manufacturing facility we are opening…

Read More >>

Aspen presented with the Ubuntu Economic Diplomacy (Africa) Award

March 22, 2018

Cape Town – JSE Limited-listed Aspen Pharmacare (APN), South Africa’s largest pharmaceutical company, was presented with the Economic Diplomacy (Africa) Award by the South African Government at the prestigious 4th annual Ubuntu Awards, held in Cape Town on 22 March 2018. Accepting the award from Lindiwe Sisulu, Minister of International Relations and Cooperations (“Dirco”) on…

Read More >>

Aspen delivers double digit revenue and earnings growth

March 8, 2018

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced favourable results for the six months ended 31 December 2017. Aspen Interim Results release March 2018

Read More >>

CNBC Exclusive with Aspen CEO Stephen Saad

January 23, 2018

Aspen Pharmacare billionaire Steven Saad opens up with the inside story of the fall of his shares. Exclusive on CNBC Africa first in business worldwide. CNBC Exclusive with Aspen CEO Stephen Saad from Aspen Pharmacare Pty Limited on Vimeo.

Read More >>

Aspen increases revenue 16% to R41.2 bn

September 14, 2017

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced pleasing results for the year ended 30 June 2017. Download (PDF 86.7KB)

Read More >>

Financial Mail cover story – 22 June 2017

June 26, 2017

Price gouging is not in Aspen’s DNA, says founder Stephen Saad, incensed at the thought that his company would exploit the sick. But Aspen’s predicament, and that of all drug firms, boils down to the tension between a drug company’s perceived responsibility to provide life-saving drugs to patients at a reasonable price, and its natural…

Read More >>

Partnering with the South African Department of Health to Enhance Public Healthcare

June 9, 2017

One of Aspen’s key business imperatives is the creation of stakeholder value. The communities Aspen operates within remain amongst the Group’s most important stakeholders, with healthcare being one of the key aspects to ensuring sustainable communities. While South Africa is currently burdened with one of the world’s most disproportionate disease profiles, it also has enthusiastic…

Read More >>

Aspen cleared of alleged anti-competitive behavior by DA

May 29, 2017

Durban – JSE Limited-listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has welcomed the statement issued by the Democratic Alliance (“DA”) earlier today in which it has confirmed that it is satisfied that there is no evidence that Aspen has engaged in alleged anti-competitive behavior as per the DA’s statement issued…

Read More >>

Aspen concludes strategic M.O.U with the Russian Federation

May 29, 2017

Windhoek, Namibia – JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“M.O.U”) has been concluded between Aspen’s Russian business and the Vladivostok Far Eastern Federal University (“F.E.F.U”). The Deputy Prime Minister of Russia Mr. Yury Trutnev, who has delegated authority from the…

Read More >>

Statement in response to The Times of London report on 20 May 2017 on Florinef

May 20, 2017

Having noted the report published in The Times of London on 20 May 2017 titled “Massive price rise for vital drug put pets’ lives at risk”, Aspen wishes to express its disappointment and concern that much of the information and clarification it provided to The Times’ Billy Kenber prior to the report being published has…

Read More >>